Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MDG1011 |
Synonyms | |
Therapy Description |
MDG1011 is T lymphocytes engineered to express preferentially expressed antigen in melanoma (PRAME)-specific TCR coupled to the CD3 signaling complex, which may induce death of PRAME-expressing tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MDG1011 | MDG 1011|MDG-1011 | MDG1011 is T lymphocytes engineered to express preferentially expressed antigen in melanoma (PRAME)-specific TCR coupled to the CD3 signaling complex, which may induce death of PRAME-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03503968 | Phase Ib/II | MDG1011 | TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms | Terminated | DEU | 0 |